Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era

Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, outlines the results of a retrospective analysis evaluating the prognostic value of circulating peripheral blood blasts in cohorts of patients with primary myelofibrosis who were treated with/without ruxolitinib. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.